On November 12, 2026 Immix Biopharma, Inc. ("Immix", the "Company", "we" or "us"), a global leader in AL amyloidosis, reported an update on corporate progress and financial results for the quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent NXC-201 Progress

– Positive clinical data: 89% complete response rate was reported across all 45 NEXICART-2 patients, with MRD-negativity indicating potential to reach up to 98% complete response rate in the future.
– Immix continues to advance its AL Amyloidosis launch readiness activities across commercial site activation, provider and payer engagement, manufacturing activities, and healthcare professional education.
Immix plans for its BLA submission in mid-2027, and NEXICART-3 front line trial initiation in the first half of 2027.

Interim NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting

On Monday, December 14, 2026, NXC-201 NEXICART-2 interim clinical data will be presented at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in New Orleans, LA.

Commercial Launch Preparation Continues with Strengthened Team

Immix has appointed David He, MD, PhD as Senior Vice President, Head of Technical Operations. Dr. He has contributed in a senior role to two approved BCMA CAR-Ts, CARVYKTI and FUCASO. Dr. He will lead chemistry, manufacturing, and controls at Immix, further accelerating the Company’s planned path to commercialization. Prior to Immix, Dr. He served as the Chief Technology Officer from pre-BLA to commercial-stage at IASO Biotherapeutics and as the Vice President, Technical Operations at Legend Biotech, as well as in a senior chemistry, manufacturing, and controls positions at Boehringer Ingelheim, and other senior roles.

Immix has appointed Karin McIntosh as Senior Vice President, Head of Regulatory Affairs. Karin has contributed to multiple FDA drug programs, including JANUVIA (FDA+EMA), EMFLAZA (FDA), ELZONRIS (FDA+EMA), and most recently, the approval of TREGZI (FDA, 2026). Karin will lead regulatory affairs at Immix in the United States and globally. Prior to Immix, Karin was Vice President, Head of Regulatory Affairs at Orca Bio and held senior regulatory positions at Stemline Therapeutics, PTC Therapeutics, Merck, and Pfizer.

Additionally, Immix has appointed additional key team members across its Commercial, Regulatory, Quality, Medical Affairs teams, and as Medical Science Liaisons.

Upcoming Events

– In addition to NEXICART-2 interim clinical data being presented at ASH (Free ASH Whitepaper) on Monday December 14, 2026, the Company will also present at the 45th Annual J.P. Morgan Healthcare Conference being held in San Francisco from January 11 – 14, 2027.
Financial Results for the Third Quarter Ended September 30, 2026

– Immix reported $340.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which is expected to provide operating runway into mid-2028.
– Immix reported $15.9 million in operating expenses for the third quarter ended September 30, 2026.
About AL Amyloidosis
Amyloid light-chain (AL) amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains that build up in organs including the heart, kidney, and liver, causing organ failure and death.

AL amyloidosis is the most common form of amyloidosis according to the National Institutes of Health. The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 30,506 patients in 2026.

The Amyloidosis market was $6.2 billion in 2025, and is expected to reach $6.6 billion in 2026, according to Grand View Research.

About NXC-201
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a proprietary CD3ζ, CD8 hinge and binder "digital filter" designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.

(Press release, Immix Biopharma, NOV 12, 2026, View Source [SID1234674674])